Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096355 | 0.83 | TP53 (0.51) | SMN1; SMN2HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL17399043 | 0.81 | TP53 (0.49) | HPGDTP53POLB | |
| SCHEMBL28433847 | 0.81 | KMT2A (0.46) | SMN1; SMN2HPGDNPC1RAB9ADGAT2 | |
| SCHEMBL2265211 | 0.80 | IMPDH2 (0.57) | HPGDIMPDH2TP53POLBNAMPT | |
| SCHEMBL4887331 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2HPGDNPC1RAB9AIMPDH2 | |
| SCHEMBL13830587 | 0.79 | TP53 (0.50) | SMN1; SMN2HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL29617015 | 0.78 | TP53 (0.62) | SMN1; SMN2HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL4193217 | 0.76 | TP53 (0.61) | HPGDTP53POLB | |
| SCHEMBL14028923 | 0.76 | PTGER1 (0.47) | SMN1; SMN2HPGDNPC1RAB9ADGAT2 | |
| SCHEMBL6225292 | 0.76 | KDM4E (0.57) | HPGDKDM4ELMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| EP-1670756-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037786-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | SMN1; SMN2 674/4885HPGD 87/4885NPC1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.